News – Page 958 – Endpoints News

Senators seek changes to FDA guidance to speed entry of insulin biosimilars

7 years ago

Building on momentum from positive diabetes data, Zafgen scoops Biogen alum Priya Singhal as head of R&D

7 years ago

As scrutiny into drug prices intensifies, Lilly launches half price Humalog; BioXcel, Nektar expand collab to include ...

7 years ago

Vertex’s 3-year feud with NICE is about to come to a head as CEO Leiden heads to London

7 years ago

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

7 years ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel ...

7 years ago

Ascendis Pharma offers positive surprise as its tech not just equals, but improves outcomes in key study

7 years ago

After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug

7 years ago

Appetite for gene therapies gains momentum, as Biogen plans $800M buyout of Nightstar Therapeutics

7 years ago

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

7 years ago

ReViral taps Seth Hetherington to guide upcoming PhIIa; Incyte, Aquinox execs move to AI shop Notable Labs

7 years ago

The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers

7 years ago

ImmunoGen's lead armed antibody falters in key ovarian cancer test as a monotherapy — shares crash

7 years ago

Philippines DOJ preps criminal charges for Sanofi, health officials involved in the Dengvaxia mess

7 years ago

After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application

7 years ago

Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

7 years ago

Eager to think bigger than China, Ascletis woos top Merck exec to run R&D

7 years ago

Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision

7 years ago

Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward

7 years ago

Robotic pill tech found to be safe, tolerable in early human study, paving ground for oral biologics

7 years ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

7 years ago

Looking to capitalize on genetic modifiers, Maze Therapeutics launches with $191M in financing led by Arch, Third ...

7 years ago

Ahead of key NASH readout, France's Genfit readies plans for $100M US IPO

7 years ago

First page Previous page 955 956 957958959 960 961 Next page Last page